When was Melinta Therapeutics founded?

Melinta Therapeutics was founded in 2000 and raised its 1st funding round 1 year after it was founded.

Where is Melinta Therapeutics located?

Melinta Therapeutics is headquartered in Morristown, United States. It is registered at Lincolnshire, Illinois.

Who is the current CEO of Melinta Therapeutics?

Christine Ann Miller of Melinta Therapeutics.

How many employees does Melinta Therapeutics have?

As of Jul 31, 2026, the latest employee count at Melinta Therapeutics is 67.

Is Melinta Therapeutics a funded company?

Melinta Therapeutics is a funded company, having raised a total of $186M across 15 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Dec 31, 2001.

How much is Melinta Therapeutics worth?

The last known valuation of Melinta Therapeutics was $***** as of Aug 07, 2025.

When was the latest funding round of Melinta Therapeutics?

Melinta Therapeutics' latest funding was a $***** Post IPO round on Feb 22, 2019, with participation from 1 investor. Its primary sector is Infectious Diseases. In United States, the Infectious Diseases sector has seen $880M in funding in 2026 to date.

Where does Melinta Therapeutics rank among its competitors?

Melinta Therapeutics ranks 4th amongst 212 active competitors, of which 77 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Vedanta Biosciences, which secured $60M in Aug, 2026.

Who are the top competitors of Melinta Therapeutics?

Melinta Therapeutics' top competitors include Spero Therapeutics, Locus Biosciences and LimmaTech Biologics. Among them, Vedanta Biosciences secured the most recent funding round in August, 2026.

Melinta Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Melinta Therapeutics is an acquired company based in Morristown (United States), founded in 2000 by Harry H Penner. It operates as a Developer of therapeutics for antibiotic-resistant infections. Melinta Therapeutics has raised $186M in funding from investors like Warburg Pincus, SR One and Oxford Bioscience Partners, with last known valuation of $*****. The company has 212 active competitors, including 77 funded and 40 that have exited. Its top competitors include companies like Spero Therapeutics, Locus Biosciences and LimmaTech Biologics.

Company Details

Developer of therapeutics for antibiotic-resistant infections. The company develops broad-spectrum antibiotics like Baxdela, Vabomere, Orbactiv, and Rezzayo for hospital and acute care settings. It emphasizes a patient-focused portfolio of commercial-stage antimicrobials and antifungals.

Social
Email ID: *****@melinta.com
Phone Number: +1 **********
Registered Address: Lincolnshire, Illinois

Key Metrics

Founded Year

2000

Location

Morristown, United States

Stage

Acquired

Total Funding

$186M in 15 rounds

Latest Funding Round

Post IPO, Feb 22, 2019, $*****

Last Known Valuation

$***** as on Aug 07, 2025

Investors

Warburg Pincus & 17 more

Ranked

4^th among 212 active competitors

Employee Count

67 as on Jul 31, 2026

Similar Companies

Spero Therapeutics & 264 more

Exit Details

Acquired by CorMedix (Aug 07, 2025)

View Melinta Therapeutics' full profile

Melinta Therapeutics is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Melinta Therapeutics, Inc CIN: 06-1599437 , United States, Active	May 15, 2008	-	290 (As on Feb 28, 2019)	-
Melinta Therapeutics, Llc CIN: 10262113 , United States, Active	Feb 06, 2024	-	-	-
Melinta Therapeutics, Inc. CIN: 61599437 , United States, Active	Dec 31, 1999	-	151 (As on Dec 31, 2024)	-
MELINTA THERAPEUTICS, INC. /NEW/ CIN: 1461993 , United States, Active		$50M - $100M (As on Dec 31, 2018)	-	-

Melinta Therapeutics got acquired by CorMedix on Aug 07, 2025 at an acquisition amount of $*****.

Click here to take a look at Melinta Therapeutics's acquisition in detail

Melinta Therapeutics has raised a total funding of $186M over 15 rounds. Its first funding round was on Dec 31, 2001. Its latest funding round was a Post IPO round on Feb 22, 2019 for $*****. 1 investor participated in its latest round. Melinta Therapeutics has 18 institutional investors.

Here is the list of recent funding rounds of Melinta Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 22, 2019	5292108	Post IPO	2815750	2206037	3077584	2269134
Jan 19, 2018	6364926	Post IPO	3835301	6833836	2401744	7006207
Nov 20, 2017	4814409	Post IPO	5595126	4310880	4281224	4225135

Access funding benchmarks and valuations. Sign up today!

View details of Melinta Therapeutics's funding rounds and investors

The founders of Melinta Therapeutics is Harry H Penner. Christine Ann Miller is the CEO of Melinta Therapeutics.

Here are the details of Melinta Therapeutics' key team members:

Harry H Penner: Former Co-Founder of Melinta Therapeutics.
Christine Ann Miller: CEO of Melinta Therapeutics.

View details of Melinta Therapeutics's Founder profiles and Board Members

Melinta Therapeutics' employee count trend

Melinta Therapeutics has 67 employees as of Jul 26. Here is Melinta Therapeutics's employee count trend over the years:

Employee count trend for Melinta Therapeutics

Uncover Melinta Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Melinta Therapeutics include Spero Therapeutics, Locus Biosciences and LimmaTech Biologics. Here is the list of Top 10 competitors of Melinta Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Spero Therapeutics 2013, Cambridge (United States), Public	Developer of therapeutics for drug-resistant bacterial infections	$115M	Atlas Venture, Partners Health Care Innovation ... & 16 others	69/100
2nd	Locus Biosciences 2015, Raleigh (United States), Series B	Developer of therapeutics for infectious disease and inflammatory indications	$67.3M	Artis Ventures, Illumina & 13 others	64/100
3rd	LimmaTech Biologics 2015, Schlieren (Switzerland), Acquired	Developing bioconjugate vaccines using glycoengineering and protein glycosylation techniques	$40M	REPAIR Impact Fund, Tenmile & 4 others	63/100
4th	Melinta Therapeutics 2000, Morristown (United States), Acquired	Developer of therapeutics for antibiotic-resistant infections	$186M	Oberland Capital, Saints Capital & 16 others	61/100
5th	Paratek Pharma 1996, Boston (United States), Acquired	Developer of therapeutics for antimicrobial resistant infections	$96.5M	Phase4 Partners, Athyrium Capital Management ... & 25 others	61/100
6th	Everest Medicines 2017, New York City (United States), Public	Developer of drugs for the treatment of cancer	$313M	RA Capital Management, Hillhouse & 12 others	61/100
7th	Bioversys 2008, Basel (Switzerland), Public	Developer of therapeutics for Antimicrobial Resistance	$62.5M	AMR Action Fund, Wellcome Trust & 10 others	61/100
8th	MicuRx Pharmaceuticals 2007, Foster City (United States), Series E	Develops antibiotics against multidrug-resistant (MDR) superbug infections	$272M	BioVeda China Fund, Legend Capital & 9 others	60/100
9th	Vedanta Biosciences 2010, Cambridge (United States), Series E	Developer of therapeutics to treat infectious diseases	$410M	Invesco, Seventure Partners & 40 others	59/100
10th	smartbax 2021, Munich (Germany), Seed	Developer of multi-targeted antibacterial compounds	$7.51M	Anobis Asset, Bayern Kapital & 4 others	59/100